Historical Immunization Log

A chronological record of U.S. federal vaccine recommendations from 1948 to 2026.

Evidentiary labels for this page: [Documented Official Data] and [Institutional History]. This log tracks the evolution of the U.S. childhood immunization schedule, documenting the addition of new vaccine platforms, regulatory milestones, and changes in public health policy. All entries reference documented federal actions and published institutional records.

Era 1: Foundation of Universal Vaccination (1940s–1960s)

The early federal schedule focused on high-mortality childhood diseases, establishing the baseline for universal public health interventions.

1948 — DTP Licensed

The first combination vaccine for Diphtheria, Tetanus, and Pertussis is licensed, standardizing the pediatric injection series.

1955 — Salk Polio Vaccine (IPV)

Following the largest clinical trial in U.S. history, the Inactivated Poliovirus Vaccine is licensed and recommended for universal use to eliminate paralytic polio.

1963 — Measles Vaccine

The first live-attenuated measles vaccine is licensed, beginning the transition toward universal measles protection.

1967/1969 — Mumps and Rubella Vaccines

Individual vaccines for Mumps and Rubella are licensed. Federal policy begins focusing on the prevention of Congenital Rubella Syndrome.

Era 2: Combination and Consolidation (1970s–1985)

This era introduced multi-antigen combinations designed to reduce the number of required injections while expanding protection.

1971 — MMR Combination Vaccine

Measles, Mumps, and Rubella vaccines are consolidated into a single injection, becoming the standard for pediatric immunization.

1972 — Smallpox Vaccination Discontinued

Routine smallpox vaccination of children is discontinued in the United States following successful domestic eradication of the disease.

1985 — Hib Vaccine (Pediatric)

The first vaccine against Haemophilus influenzae type b is recommended for children 24 months and older, targeting bacterial meningitis and pneumonia.

Era 3: Institutional Framework and Schedule Growth (1986–2000)

This period is marked by the creation of the modern legal framework for vaccine injury compensation and a significant expansion of the universal childhood schedule.

1986 — National Childhood Vaccine Injury Act (NCVIA)

Congress enacts the NCVIA, creating the Vaccine Injury Compensation Program (VICP) as a no-fault legal alternative for injury claims. The Act also mandates that healthcare providers distribute Vaccine Information Statements (VIS) for all recommended vaccinations. See our VICP page at /legal/vicp and Legal History page at /legal/history.

1991 — Hepatitis B Added to Infant Schedule

Hepatitis B vaccine is added to the infant schedule as a universal recommendation, including a birth dose, to prevent chronic liver disease and cirrhosis.

1995 — Varicella (Chickenpox) Vaccine

A live-attenuated vaccine for Varicella is added to the universal pediatric schedule for children aged 12–15 months.

1997 — DTP to DTaP Transition

ACIP formally recommends the acellular pertussis vaccine (DTaP) for all five doses in the childhood series, replacing the whole-cell DTP vaccine to reduce local injection-site reactions. DTaP had been FDA-approved since 1991 and was gradually phased in during the mid-1990s.

1998 — Wakefield Study Published

The Lancet publishes a study by Andrew Wakefield claiming an association between the MMR vaccine and autism. The study generated significant public concern regarding MMR vaccination rates. (See Era 4 for retraction.)

1999 — RotaShield Withdrawal

The first rotavirus vaccine (RotaShield) is voluntarily withdrawn from the U.S. market after post-market surveillance through VAERS and VSD detects an association with intussusception, a type of bowel obstruction. This withdrawal is a landmark example of the safety monitoring system identifying and responding to a post-licensure safety signal. See our Post-Market Surveillance page at /regulatory/post-market-surveillance.

Era 4: Modernization and Technology (2001–2020)

Advancements in vaccine technology and safety monitoring coincided with new challenges regarding public confidence and emergency liability frameworks.

2000 — Pneumococcal Conjugate Vaccine (PCV7)

The first conjugate vaccine for Streptococcus pneumoniae is added to the schedule, targeting bacterial pneumonia and meningitis in young children.

2005 — PREP Act Enacted

Congress enacts the Public Readiness and Emergency Preparedness Act, providing liability immunity for manufacturers, distributors, and administrators of medical countermeasures — including vaccines — during declared public health emergencies. The PREP Act creates the Countermeasures Injury Compensation Program (CICP) as the compensation pathway for injuries from covered countermeasures. See our PREP Act page at /regulatory/prep-act.

2006 — Rotavirus and HPV Vaccines

New oral rotavirus vaccines (RotaTeq and Rotarix) are added to the schedule, replacing the withdrawn RotaShield. The HPV vaccine (Gardasil) is also recommended for cancer prevention.

2010 — Annual Influenza Recommendation Expanded

ACIP expands the annual influenza vaccination recommendation to include all children aged 6 months and older.

2010 — Wakefield Study Retracted

The Lancet formally retracts Andrew Wakefield's 1998 study following findings of research misconduct by the UK General Medical Council. Wakefield's medical license was revoked. Multiple large-scale studies conducted before and after the retraction found no association between MMR vaccination and autism. See our Autism-MMR Controversies page at /controversies/autism-mmr.

Era 5: Platform Innovation and Schedule Reorganization (2021–2026)

This era is defined by the deployment of genetic-based vaccine platforms and the reorganization of federal recommendations toward a three-tier framework incorporating individualized clinical consultation.

2021 — mRNA Vaccine Authorization

Genetic-based mRNA platforms for COVID-19 receive Emergency Use Authorization (EUA) from the FDA, followed by full Biologics License Application (BLA) approval in late 2021 and 2022. See our EUA page at /regulatory/fda/eua and BLA page at /regulatory/fda/biologics-license.

2025–2026 — saRNA and Mucosal Platforms

Self-amplifying RNA (saRNA) and nasal-delivery vaccine candidates advance through clinical trials, representing the next generation of vaccine delivery technology. As of early 2026, saRNA candidates are under clinical evaluation but have not yet received full FDA licensure.

January 5, 2026 — The SCDM Reorganization

The Department of Health and Human Services reorganizes the federal childhood immunization schedule into a three-tier system:

Note: Meningococcal disease, Hepatitis A, and Hepatitis B are dually categorized, appearing in both the high-risk and SCDM tiers depending on age, medical history, and exposure risk.

For a detailed analysis of the 2026 reorganization, see our Citizen's Guide at /learn/guides/2026-schedule and ACIP page at /regulatory/acip.

Schedule Growth Summary: Recommended Doses by Era

The following table summarizes the approximate number of diseases targeted and total recommended doses from birth through age 18 at key benchmark years.

Benchmark Year Diseases Targeted Approximate Doses (Birth–18) Primary Source
1960 4 (Smallpox, DTP, Polio, Measles*) ~8 CDC Historical Immunization Schedule Archives. *Measles vaccine licensed 1963; included here as representative of the early 1960s expansion.
1983 7 ~11 1983 ACIP Recommended Childhood Immunization Schedule
1995 10 ~19 1995 ACIP Recommended Childhood Immunization Schedule
2026 (Tier 1 only) 11 ~23 2026 HHS/CDC Reorganized Schedule. Excludes annual respiratory vaccines and Tier 2/Tier 3 additions.

Note: Dose counts are approximate and reflect the recommended primary series plus boosters for the benchmark year. Counts may vary based on combination vaccine availability and catch-up schedule provisions. Readers should consult CDC Historical Immunization Schedule Archives for exact published schedules.

Sources and Citations